- Home
- SYBX vs MTVA Comparison
SYBX vs MTVA Comparison
Compare SYBX & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBX
- MTVA
- Stock Information
- Founded
- SYBX N/A
- MTVA 2014
- Country
- SYBX United States
- MTVA United States
- Employees
- SYBX N/A
- MTVA N/A
- Industry
- SYBX Biotechnology: Pharmaceutical Preparations
- MTVA
- Sector
- SYBX Health Care
- MTVA
- Exchange
- SYBX Nasdaq
- MTVA NYSE
- Market Cap
- SYBX 13.6M
- MTVA 14.3M
- IPO Year
- SYBX N/A
- MTVA N/A
- Fundamental
- Price
- SYBX $1.20
- MTVA $0.70
- Analyst Decision
- SYBX
- MTVA Strong Buy
- Analyst Count
- SYBX 0
- MTVA 2
- Target Price
- SYBX N/A
- MTVA $7.50
- AVG Volume (30 Days)
- SYBX 6.9K
- MTVA 110.1K
- Earning Date
- SYBX 08-07-2025
- MTVA 08-13-2025
- Dividend Yield
- SYBX N/A
- MTVA N/A
- EPS Growth
- SYBX N/A
- MTVA N/A
- EPS
- SYBX 0.21
- MTVA N/A
- Revenue
- SYBX N/A
- MTVA N/A
- Revenue This Year
- SYBX N/A
- MTVA N/A
- Revenue Next Year
- SYBX N/A
- MTVA N/A
- P/E Ratio
- SYBX $5.92
- MTVA N/A
- Revenue Growth
- SYBX N/A
- MTVA N/A
- 52 Week Low
- SYBX $0.90
- MTVA $0.60
- 52 Week High
- SYBX $1.88
- MTVA $5.16
- Technical
- Relative Strength Index (RSI)
- SYBX 54.75
- MTVA N/A
- Support Level
- SYBX $1.18
- MTVA N/A
- Resistance Level
- SYBX $1.27
- MTVA N/A
- Average True Range (ATR)
- SYBX 0.05
- MTVA 0.00
- MACD
- SYBX -0.00
- MTVA 0.00
- Stochastic Oscillator
- SYBX 58.33
- MTVA 0.00
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.